A Phase II Study of Total Neoadjuvant Chmoradiation Treatment Plus SHR1210 for High-risk Locally Advanced Rectal Cancer and Biomarker Screening Base on Neoantigen
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Jun 2022 Status changed from recruiting to completed as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology